/ /

  • linkedin
  • Increase Font
  • Sharebar

    Tracking treatment adherence in newly diagnosed open-angle glaucoma

    Claims data point to significant gap between diagnosis, medical/surgical therapies


    Study limitations were those that are often associated with insurance claims data analyses, such as whether patients received prescriptions but did not fill them, or whether they used their medications as prescribed, she noted.

    Regarding the large percentage of patients who were untreated at the 4-year time point, another study limitation was that the current analysis does not include data from office visits, and it is unknown whether the 17% of patients who were untreated missed visits or did not pick up their medications, or if other factors played a role in their lack of treatment. Future analysis will incorporate office visit data and further characterize the untreated patients, Dr. Schwartz noted.

    More: Top apps for ophthalmologists

    “Even in the setting of continuous insurance coverage, adherence with topical therapy remained limited, which was consistent with previous data,” Dr. Schwartz said. “Forty-five percent of patients undergoing initial laser trabeculoplasty were not prescribed additional topical medication.”

    This study lends further data to support the need for long-acting medication and/or alternative procedures that reduce or eliminate the adherence component, Dr. Schwartz concluded.



    Gail F. Schwartz, MD

    E: [email protected]

    Dr. Schwartz has received speaker honoraria and consulting fees from Allergan. This study was sponsored by Allergan plc, Dublin, Ireland. Dr. Schwartz was joined in this study by Degang Wang, Guo Li, and Hitesh Chandwani, who were employees of Allergan at the time of the study.


    New Call-to-action


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results